PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration - PubMed (original) (raw)
PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration
Carmen J Marsit et al. Hum Pathol. 2005 Jul.
Abstract
The tumor suppressor PTEN encodes a lipid phosphatase that negatively regulates the phosphatidylinositol 3-kinase/AKT cell survival pathway. Mutations of this gene are common in brain, prostate, endometrial, and gastric cancers but occur rarely in non-small-cell lung cancer (NSCLC), although the PTEN protein is often lost in lung tumors. We have studied hypermethylation of the PTEN promoter, loss of heterozygosity (LOH) at microsatellites in chromosome 10q23 (surrounding and intragenic to the PTEN locus), and hypermethylation of PTEN's highly homologous pseudogene, PTENP1, and their association with PTEN protein loss in a surgical case series study of primary NSCLC. PTEN protein expression was reduced or lost in 74% (86/117) of tumors, with loss occurring more often in well to moderately differentiated tumors. In squamous cell carcinomas, PTEN loss occurred significantly more often in early-stage (stage I or II) disease. PTEN protein loss also occurred more frequently in tumors with low to no aberrant TP53 staining. Methylation of PTEN occurred in 26% (39/151) of tumors, and LOH at 10q23 was rare, occurring in only 19% (17/90) of informative tumors. Neither methylation nor LOH was a significant predictor of PTEN protein expression, although LOH occurred exclusively in early-stage disease. In NSCLC, loss of PTEN protein expression occurs frequently, although the mechanism responsible for loss is not clearly attributable to deletion or epigenetic silencing. PTEN loss may also be a favorable prognostic marker, although further studies are needed to confirm this finding.
Similar articles
- Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Soria JC, et al. Clin Cancer Res. 2002 May;8(5):1178-84. Clin Cancer Res. 2002. PMID: 12006535 - Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG. Byun DS, et al. Int J Cancer. 2003 Apr 10;104(3):318-27. doi: 10.1002/ijc.10962. Int J Cancer. 2003. PMID: 12569555 - Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Kurose K, et al. Am J Pathol. 2001 Jun;158(6):2097-106. doi: 10.1016/S0002-9440(10)64681-0. Am J Pathol. 2001. PMID: 11395387 Free PMC article. - PTEN regulatory functions in tumor suppression and cell biology.
Chu EC, Tarnawski AS. Chu EC, et al. Med Sci Monit. 2004 Oct;10(10):RA235-41. Epub 2004 Sep 23. Med Sci Monit. 2004. PMID: 15448614 Review. - The role of PTEN in the progression and survival of prostate cancer.
Deocampo ND, Huang H, Tindall DJ. Deocampo ND, et al. Minerva Endocrinol. 2003 Jun;28(2):145-53. Minerva Endocrinol. 2003. PMID: 12717346 Review.
Cited by
- Expression and clinical significance of microRNA-21, PTEN and p27 in cancer tissues of patients with non-small cell lung cancer.
Yang L, Yang J. Yang L, et al. Oncol Lett. 2020 Oct;20(4):49. doi: 10.3892/ol.2020.11910. Epub 2020 Jul 24. Oncol Lett. 2020. PMID: 32802169 Free PMC article. - IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review.
Galani V, Kastamoulas M, Varouktsi A, Lampri E, Mitselou A, Arvanitis DL. Galani V, et al. Clin Exp Med. 2017 Aug;17(3):281-289. doi: 10.1007/s10238-016-0432-3. Epub 2016 Jul 14. Clin Exp Med. 2017. PMID: 27416926 Review. - Mechanistic Understanding of Curcumin's Therapeutic Effects in Lung Cancer.
Wan Mohd Tajuddin WNB, Lajis NH, Abas F, Othman I, Naidu R. Wan Mohd Tajuddin WNB, et al. Nutrients. 2019 Dec 6;11(12):2989. doi: 10.3390/nu11122989. Nutrients. 2019. PMID: 31817718 Free PMC article. Review. - PTEN Tumor-Suppressor: The Dam of Stemness in Cancer.
Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. Luongo F, et al. Cancers (Basel). 2019 Jul 30;11(8):1076. doi: 10.3390/cancers11081076. Cancers (Basel). 2019. PMID: 31366089 Free PMC article. Review. - Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, Kashida Y, Yamaguchi M, Chang GD, Chen CS. Wang YC, et al. Cancer Res. 2008 Apr 15;68(8):2820-30. doi: 10.1158/0008-5472.CAN-07-1336. Cancer Res. 2008. PMID: 18413750 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous